MedTrace Logo

Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)

NCT04742010 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-06-10

No results posted yet for this study

Summary

In a randomised placebo-controlled trial assess effects of zoledronic acid for prevention of bone and muscle loss after bariatric surgery.

Conditions

  • Bone Loss
  • Muscle Atrophy
  • Bariatric Surgery

Interventions

DRUG

Zoledronic Acid

* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted) * Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo) * Administration: slow intravenous infusion with a duration of at least 15 minutes

DRUG

Placebo

as above

Sponsors & Collaborators

  • Research Unit of Health Sciences, Hospital of South West Jutland

    collaborator UNKNOWN

  • Department of Regional Health Research, University of Southern Denmark

    collaborator UNKNOWN

  • OPEN - Odense Patient data Explorative Network, The University of Southern Denmark, Odense, Denmark

    collaborator UNKNOWN

  • Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, 6700 Esbjerg, Denmark

    collaborator UNKNOWN

  • Odense University Hospital

    collaborator OTHER

  • Stinus Gadegaard Hansen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-20
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04742010 on ClinicalTrials.gov